Regulus Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Regulus Therapeutics

09/08/2023 13:01

* Regulus Therapeutics Inc  RGLS.OQ  reported a quarterly
adjusted
loss of 37 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 41 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Regulus Therapeutics Inc's reported EPS for the quarter
was a
loss of 37 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Regulus Therapeutics Inc shares had fallen by 9.5% this
quarter and lost 2.9% so far this year.
    * The company reported a quarterly loss of $7.01 million.
    * Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $5.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 12:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.41          -0.37          Beat
 Mar. 31 2023      -0.44          -0.42          Beat
 Dec. 31 2022      -0.51          -0.40          Beat
 Sep. 30 2022      -0.49          -0.50          Missed